Widely used weight loss and diabetes drugs, including Ozempic and Wegovy, will carry a new warning about rare side effects that sometimes lead to permanent vision loss. 

The Food and Drug Administration said the warning will be added to all GLP-1 drugs, which are used to treat obesity, diabetes and several other medical conditions, CBS News reported. 

The eye condition, known as non-arteritic anterior ischemic optic neuropathy, has been reported with all GLP-1 drugs. It can lead to significant vision loss, and its underlying cause isn't understood, according to the FDA. 

Researchers at the FDA began looking into the problem after a 2024 medical paper tied the condition to some patients taking semaglutide, the active drug in Novo Nordisk's Ozempic and Wegovy.